Palvella Therapeutics (PVLA) Director M Sells $1.8M of Stock
Director George M. Jenkins sold 13,152 shares of Palvella Therapeutics on October 12, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Jenkins George M, Director at Palvella Therapeutics, Inc. ($PVLA), sold 13,152 shares at an average price of $133.69, worth about $1.76 million, on October 12, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $PVLA is down 10.5% to date (from the $134.38 close on Oct 12, 2026).
PVLA
Palvella Therapeutics, Inc.
Key Points
- George M. Jenkins, a director at Palvella Therapeutics, sold 13,152 shares at an average price of $133.69 on October 12, 2026, totaling about $1.76 million.
- As of October 16, 2026, Palvella Therapeutics traded recently around $119.43, which is about 18.3% below its 50-day moving average of $146.14.
- The company has a strong buy recommendation from analysts, with a mean price target of $228.93, indicating significant potential upside.
Get $PVLA trade alerts by text
We text you when insiders, Congress or big funds trade $PVLA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Palvella Therapeutics, Inc. alert may contain errors. Disclosures
George M. Jenkins, a director at Palvella Therapeutics, Inc. (PVLA) on the NasdaqGM, sold 13,152 shares on October 12, 2026. The average sale price was $133.69, bringing the total value of the transaction to about $1,758,330.34. This sale was planned in advance under a Rule 10b5-1 plan.
Inside Jenkins's Trade
Jenkins's sale adds to a series of transactions involving company insiders. Earlier, on October 13, 2026, Jenkins sold 7,174 shares at a price of $130.36, valued at approximately $935,232. This pattern of selling may suggest a strategy to manage personal holdings or liquidity needs, rather than a negative outlook on the company’s prospects.
Other Institutional Activity in Palvella Therapeutics
Several other institutional investors have adjusted their stakes in Palvella Therapeutics recently. Jennison Associates LLC increased its position by 319,993 shares, totaling 960,619 shares valued at about $115.6 million. Conversely, Montanova Capital LLC reduced its holdings by 18,110 shares, ending with 1,135,406 shares worth approximately $136.6 million. Blackrock Inc. also grew its stake by 231,530 shares, bringing its total to 918,357 shares valued at around $110.5 million.
Palvella Therapeutics, Inc. Stock Down 6.2%
As of October 16, 2026, Palvella Therapeutics trades at about $119.43, which is significantly below its 50-day moving average of $146.14 and its 200-day average of $125.10. The stock is also about 26% below its 52-week high of $161.38, but it remains 73.2% above its 52-week low of $68.96. This performance may reflect investor sentiment as the company continues to develop its lead product candidate, QTORIN rapamycin.
Recent Earnings
Palvella Therapeutics has yet to report a profit, with a trailing twelve-month earnings per share (EPS) of -$4.85. The next earnings report is scheduled for November 11, 2026. The company is focusing on developing therapies for rare genetic skin diseases, which could impact future earnings positively if successful.
Insider Buying and Selling at Palvella Therapeutics, Inc.
In addition to Jenkins, other insiders have sold shares recently. On September 15, 2026, Jenkins himself sold 27,500 shares, valued at approximately $4.17 million. CFO Matthew Korenberg also sold 1,000 shares on June 12, 2026. These transactions show a trend of selling among insiders, which can be common for various reasons.
Analysts Set New Price Targets
On October 12, 2026, HC Wainwright & Co. maintained a buy rating on Palvella Therapeutics with a price target of $246. Chardan Capital also maintains a buy rating with a target of $240. The consensus among 15 analysts gives the stock a strong buy recommendation with a mean price target of $228.93.
About Palvella Therapeutics
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Wayne, PA. It focuses on developing therapies for serious and rare genetic skin diseases. Its lead candidate, QTORIN rapamycin, is in clinical trials for treating lymphatic malformations. The recent insider sales and ongoing trials may influence investor sentiment as the company approaches key milestones.
Bottom Line
Investors should keep an eye on upcoming earnings on November 11, 2026, as well as any further insider transactions. Jenkins's recent sales fit into a broader pattern of insider activity, which can provide insights into management's confidence in the company's future.
Related Filing Alerts
Source: Jenkins George M's Form 4 filing on $PVLA (Oct 12, 2026). Find the original filing: PVLA Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts